[2020, Mulhouse, Covid-19: a lesson in history, Europe and resilience].

In March 2020, Covid-19, caused by the severe acute respiratory syndrome coronavirus 2, struck the Haut-Rhin region with extreme violence, overwhelming hospitals and requiring the massive opening of new resuscitation beds. The military resuscitation element of the French military health service was deployed for the first time in Mulhouse (68), in eastern France. Alsace-Lorraine, a European crossroads and the birthplace of European institutions, was once again at the heart of history.

[Procoagulant hemostatic dressings and hemorrhages].

When faced with a hemorrhage, there are many ways to achieve hemostasis. War medicine and terrorist attacks have taught us the wide use of the tactical tourniquet since hemorrhagic injury is the leading cause of death, mainly in pre-hospital care. The existence of hemorrhagic areas not accessible to tourniquets and the possibility of conversion of a tourniquet by other non-ischemic local hemostasis means have demonstrated the relevance of compression by internal or external packing.

[COVID-19, drugs and hospital pharmacy].

Observation, interpretation, actions for improvement, questioning are all terms that echo the situation of caregivers since the outbreak of the COVID-19 epidemic in France at the beginning of 2020. All those involved in the healthcare chain have had to cope with the influx of patients and to show that they are capable of seeing their practices evolve on a daily basis. What was recommended a few weeks earlier could quickly become obsolete.

[Management of flows and supply shortages of health products in hospitals during the COVID-19 crisis].

The hospital pharmacy is a medico-technical department within the hospital which has been significantly affected by the COVID-19 crisis. It has been a crucial element in the supply and flow management of medicines and medical devices. The shortage of medicines, and in particular of five molecules essential for the treatment of COVID-19 patients, has resulted in stocks being managed on a national level in order to address these new and unknown challenges.

[Assessing and making safe the medicine use pathway in paediatrics].

Based on an assessment of adverse events in a follow-up care and rehabilitation unit in paediatrics, audits were carried out of the medicine use pathway. The evaluation grid taken from this study today serves as a basis for the audits carried out on the medicine use pathway on a national level.

[The analysis of the medication error, in practice].

By performing a systemic analysis of medication errors which occur in practice, the multidisciplinary teams can avoid a reoccurrence with the aid of an improvement action plan. The methods must take into account all the factors which might have contributed to or favoured the occurrence of a medication incident or accident.

[The medicine use pathway in paediatrics].

The medicine use pathway is a process which is constantly evolving in order to comply with intangible rules. As in other therapeutic fields, the drug regimen in paediatrics must tolerate no error and must be able to detect all warning signs, however minor, in order to optimise this approach.

[The pharmacopoeia for the poor of Professor Nicolas Jadelot from Nancy in 1784-1785].

In 1785, Doctor Nicolas Jadelot, a professor at the Faculty of medicine of Nancy, published a little book entitled Pharmacopée des pauvres. Four parts composed it: pharmaceutical formulas from Saint-Charles Hospital, some corrections, a table of materials and a table of the use of drugs. In octavo, the book gathered 212 pages and 342 formulas of drugs, most of the materials beeing found in plants.